The UroCuff Test: a non-invasive alternative to pressure flow studies in adult males with lower urinary tract symptoms secondary to bladder outlet obstruction (Matulewicz, 2015)

• The UroCuff has been validated as equivalent to urodynamics pressure-flow for the diagnosis of BOO.
• The positive predictive value of the UroCuff penile cuff test to diagnose BOO was found to be 92%.

Non-invasive urodynamics predicts outcome prior to surgery for prostatic obstruction (Losco, 2013)

• The UroCuff Test is a proven predictor of BPH treatment outcomes.
• Specifically, 94% of patients predicted to be obstructed had a successful outcome (p < 0.01), and 70% of patients predicted to be not obstructed had unsuccessful outcomes after surgery.

​
For a complete list of peer-reviewed clinical publications, refer to the UroCuff Summary of Supporting Evidence or go to the Sales Portal.

The American Urological Association (AUA) has updated its BPH Surgical Management Guidelines. The Guidelines include 22 Clinical Recommendations. We have highlighted four important Guideline principals that support practices using SRS Medical solutions to drive better BPH care.

Principal 1: The recommendation that BPH Procedures should be delayed until Medical Management failure has been eliminated.
Guideline language
“…clinical scenarios where surgery is indicated as the initial intervention for LUTS/BPH and should be recommended, providing other medical comorbidities do not preclude this approach.”
SRS Medical perspective
The previous AUA Guidelines recommended procedures only after medical management failure. The new Guidelines recommend consideration of earlier intervention via expanded procedure options and better diagnostics.

Principal 2: Pressure flow studies should be considered prior to intervention.
Guideline language
“Clinicians should consider pressure flow studies prior to surgical intervention for LUTS attributed to BPH when diagnostic uncertainty exists. (Expert Opinion)”
SRS Medical perspective
Diagnosing bladder function provides a physiological marker to establish a patient’s position in the BPH disease state. Interventions should occur before bladder function deteriorates, independent of symptom tolerance.

Principal 3: Both the UroLift and Rezum procedures are established standards of care.
Guideline language
Guideline statements 14,15,17,18.

Principal 4: AUA emphasizes expanded diagnostics in the future
Guideline language
“The natural history and predictive ability of various urodynamic measures, [….] is an area of great interest with substantial clinical and health care economic consequences.”
SRS Medical perspective
AUA has determined that bladder function diagnostics play a critical role in BPH management. They also indicate that the role of bladder function diagnostics will continue to expand. SRS Medical is leading the way.

Filling phase:  Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Emptying phase: Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Valsalva (optional): Lorem Ipsum is simply dummy text of the printing and typesetting industry.

The two videos below explains the basics of urodynamics.

EasyPro One Installation
Download the EP1 software at:

This is the main information that you need know when speaking to clients regarding reimbursement for The VP Test.

• The CPT Code used to bill The VP Test is 51725 – Simple Cystometrogram (CMG)
• The VP Test pays approximately $200 (Medicare National Average Payment $193.32)
• Like other diagnostic tests, it can be billed during the Global Surgery Period by using the -79 Modifier

 
Please contact Jodell if there are more detailed questions.